echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Nat Commun: Molecular signs of breast cancer in Asia reveal the specificity of the disease in the population

    Nat Commun: Molecular signs of breast cancer in Asia reveal the specificity of the disease in the population

    • Last Update: 2020-12-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Breast cancer is a heterogeneous disease, which is generally guided by histological pathology and clinical demographic characteristics.
    such as endocrine therapy in ER-plus (estrogen-positive) tumors, HER2 targeted therapy in Her2-plus tumors, and treatment of patients with poor prognosis through chemotherapy.
    molecular features of breast tumors is conducive to the development of new therapies and suitable treatment options.
    of other populations where genetic, lifestyle and environmental factors vary from previous studies (mainly among women of European descent).
    , however, studies of non-white breast cancer patients lack details.
    molecular subtype analysis of breast cancer patients in Malaysia In this study, the researchers analyzed the number of genetic mutations, transcriptions and copies in 560 malaysian breast tumor patients, and compared the incidence of breast cancer in Asian and white women.
    researchers found that the prevalence of HER2-molecule subtypes increased in patients with ER-Asian breast cancer compared to white breast cancer patients, and the prevalence was higher in patients with TP53 cell mutations.
    further study of tumor immuno-microencient analysis in breast cancer patients in Malaysia showed that the elevated immune scores of breast cancer patients in Asia indicated a potential clinical response to immunosuperative inhibitors.
    HER2 subtype and higher immune scores were associated with improved survival rates in patients, while cell mutations carrying TP53 and ER-plus status corresponded to poor survival rates in patients.
    , the findings reveal that differences in different populations provide insights into the understanding of breast cancer and provide a basis for precision medicine in different populations.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.